Common Technical Document

Common Technical Document
Name	Common Technical Document
Genre	Regulatory submission format
Publisher	International Council for Harmonisation, European Medicines Agency, United States Food and Drug Administration
Pub date	1989–present

Common Technical Document

The Common Technical Document is an internationally harmonized format for regulatory submissions used in medicinal product registration across multiple jurisdictions. It streamlines dossiers for European Medicines Agency, United States Food and Drug Administration, Pharmaceuticals and Medical Devices Agency reviews and facilitates interaction among regulators such as Health Canada and Therapeutic Goods Administration. The document supports convergence among stakeholders including industry trade groups like the International Federation of Pharmaceutical Manufacturers & Associations, standards bodies such as the International Council for Harmonisation, and global donors like the Bill & Melinda Gates Foundation.

Overview

The document provides a standardized layout for clinical, nonclinical, and quality information enabling assessors from agencies like European Medicines Agency, United States Food and Drug Administration, Medicines and Healthcare products Regulatory Agency to navigate submissions efficiently. Sponsors—pharmaceutical companies such as GlaxoSmithKline, Pfizer, Roche, biotechnology firms like Amgen and contract research organizations including QuintilesIMS—use the format to prepare dossiers for regulators in regions represented by entities such as Health Canada, Therapeutic Goods Administration, and the South African Health Products Regulatory Authority. The approach supports international programs involving the World Health Organization, regional initiatives like the African Medicines Regulatory Harmonization Program, and multilateral donors including the Global Fund.

History and Development

Origins trace to harmonization efforts led by regulatory and industry stakeholders including the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use and later the International Council for Harmonisation. Early milestones involved collaboration among the European Commission, United States Department of Health and Human Services, and counterpart agencies in Japan such as the Pharmaceuticals and Medical Devices Agency. Subsequent expansions involved dialogues with agencies from Brazil, China, and India and programs coordinated with global health organizations like the World Health Organization and funding partners like the Bill & Melinda Gates Foundation.

Structure and Content

The format is divided into modules to organize content for regulators including the European Medicines Agency, United States Food and Drug Administration, and national bodies such as Health Canada. Modules encompass administrative information, quality documentation used by manufacturers like Novartis and Sanofi, nonclinical study reports originating from laboratories similar to Charles River Laboratories, and clinical study reports from trials conducted at centers such as Mayo Clinic and Cleveland Clinic. Sections reflect principles endorsed by the International Council for Harmonisation and reference guidances issued by authorities such as the European Commission and the United States Department of Health and Human Services.

Regulatory Use and Acceptance

Regulatory agencies including the European Medicines Agency, United States Food and Drug Administration, Pharmaceuticals and Medical Devices Agency, Health Canada, Therapeutic Goods Administration, and regional regulators like the African Medicines Agency accept dossiers structured under the format to varying extents. Multinational companies such as Johnson & Johnson and generic manufacturers like Teva Pharmaceutical Industries rely on the format to file for marketing authorization in jurisdictions governed by laws like the Food, Drug, and Cosmetic Act and directives from the European Commission. International procurement bodies including UNICEF and Gavi, the Vaccine Alliance also reference harmonized dossiers when evaluating product quality and safety.

Preparation and Submission Standards

Preparation follows technical guidances from organizations such as the International Council for Harmonisation and administrative procedures from authorities like the European Medicines Agency and United States Food and Drug Administration. Sponsors coordinate with contract research organizations such as Parexel and testing laboratories like Covance to compile modules that include chemistry, manufacturing, and controls data from manufacturers such as Boehringer Ingelheim and clinical data from trial networks affiliated with institutions like Johns Hopkins University and Harvard Medical School. Electronic submission standards align with specifications used by agencies such as the European Medicines Agency and initiatives like the Common Electronic Submission Gateway.

Implementation by Region and Agency

Adoption varies: the European Medicines Agency and United States Food and Drug Administration have long-standing pathways compatible with the format, while regulators in Brazil, China, India, and members of the Association of Southeast Asian Nations adapt elements alongside national requirements. Regional harmonization efforts involve organizations like the African Union, the Pan American Health Organization, and networks of regulators coordinated by the World Health Organization. Industry stakeholders including Pfizer, AstraZeneca, and generic firms engage with national agencies such as ANVISA and China National Medical Products Administration to align submissions.

Criticisms and Challenges

Critiques involve resource burdens cited by smaller manufacturers and regulators such as capacity constraints faced by agencies in Africa and parts of Asia, concerns raised by public-interest groups and academics at institutions like London School of Hygiene & Tropical Medicine about transparency and access, and interoperability issues with regional e-submission systems maintained by entities like the European Medicines Agency and national health ministries. Intellectual property considerations involving corporations like Merck & Co. and data protection laws in jurisdictions such as United States and European Union complicate shared reliance models. Ongoing debate engages stakeholders from European Commission, United States Food and Drug Administration, World Health Organization, and industry consortia about modernization, capacity building, and alignment with initiatives led by organizations such as the Bill & Melinda Gates Foundation and Gavi, the Vaccine Alliance.

Category:Pharmaceutical regulation